Summary by Moomoo AI
Allarity Therapeutics, Inc., a biotechnology company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an offering of securities. The filing, dated January 18, 2024, reports that the company has already sold $400,000 worth of senior convertible promissory notes to one accredited institutional investor. The total offering amount is listed as $1,400,000, with $1,000,000 remaining to be sold. The offering is not being made in connection with a business combination transaction and is expected to last less than one year. Allarity Therapeutics has claimed an exemption under Rule 506(b) and has declined to disclose its revenue range or aggregate net asset value. The company's principal place of business is in Boston, Massachusetts, and the executive officers and directors listed include Thomas Jensen, Joan Brown, Gerald McLaughlin, Laura Benjamin, and Joseph Vazzano. The proceeds from the offering are not intended for payments to any of the named executive officers, directors, or promoters.